Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA

•HIV-1 RNA is often detected by ultrasensitive methods in patients on successful ART.•HIV-1 DNA is detected in blood cells in virtually all patients on successful ART.•Switch from NNRTI or PI to raltegravir-based ART can decrease cellular HIV-1 DNA.•Residual HIV-1 RNA is not affected by switching from NNRTI or PI to RAL-based ART.•Switching to a RAL-based regimen may help to reduce the size of the HIV reservoir.